AbbVie (ABBV) Non-Current Assets (2012 - 2026)
AbbVie (ABBV) reported Non-Current Assets of $102.9 billion for Q1 2026, down 5.12% year-over-year from $108.5 billion in Q1 2025, and down 1.87% on a QoQ basis from $104.9 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Non-Current Assets data on file, last reported at $102.9 billion in Q1 2026.
- Quarterly Non-Current Assets fell 5.12% year-over-year to $102.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $421.1 billion (down 4.69% YoY) and the FY2025 annual result came in at $104.9 billion, down 4.27% from the prior year.
- Non-Current Assets fell to $102.9 billion in Q1 2026 per ABBV's latest filing, from $104.9 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $116.7 billion in Q1 2022 and bottomed at $101.7 billion in Q4 2023.
- The 5-year median for Non-Current Assets is $108.1 billion (2024), against an average of $108.5 billion.
- The widest annual swing landed in 2024, when Non-Current Assets advanced 12.27%; it then fell 8.89% in 2025.
- Tracing ABBV's Non-Current Assets over 5 years: stood at $110.3 billion in 2022, then slipped by 7.82% to $101.7 billion in 2023, then rose by 7.74% to $109.6 billion in 2024, then fell by 4.27% to $104.9 billion in 2025, then decreased by 1.87% to $102.9 billion in 2026.
- Per Business Quant, the three latest ABBV Non-Current Assets figures stand at $102.9 billion (Q1 2026), $104.9 billion (Q4 2025), and $105.4 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 61.74 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 141.72 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 102.93 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 59.27 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 58.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.93 Bn |
| Dec 31, 2025 | 104.90 Bn |
| Sep 30, 2025 | 105.36 Bn |
| Jun 30, 2025 | 107.92 Bn |
| Mar 31, 2025 | 108.49 Bn |
| Dec 31, 2024 | 109.58 Bn |
| Sep 30, 2024 | 115.64 Bn |
| Jun 30, 2024 | 108.12 Bn |
| Mar 31, 2024 | 110.00 Bn |
| Dec 31, 2023 | 101.71 Bn |
| Sep 30, 2023 | 103.00 Bn |
| Jun 30, 2023 | 106.52 Bn |
| Mar 31, 2023 | 108.06 Bn |
| Dec 31, 2022 | 110.34 Bn |
| Sep 30, 2022 | 110.96 Bn |
| Jun 30, 2022 | 114.09 Bn |
| Mar 31, 2022 | 116.70 Bn |
| Dec 31, 2021 | 118.60 Bn |
| Sep 30, 2021 | 119.90 Bn |
| Jun 30, 2021 | 121.97 Bn |
| Mar 31, 2021 | 123.93 Bn |
| Dec 31, 2020 | 126.39 Bn |
| Sep 30, 2020 | 126.61 Bn |
| Jun 30, 2020 | 128.27 Bn |
| Mar 31, 2020 | 39.44 Bn |
| Dec 31, 2019 | 39.60 Bn |
| Sep 30, 2019 | 39.28 Bn |
| Jun 30, 2019 | 42.04 Bn |
| Mar 31, 2019 | 42.36 Bn |
| Dec 31, 2018 | 42.41 Bn |
| Sep 30, 2018 | 47.70 Bn |
| Jun 30, 2018 | 47.80 Bn |
| Mar 31, 2018 | 48.90 Bn |
| Dec 31, 2017 | 49.56 Bn |
| Sep 30, 2017 | 49.91 Bn |
| Jun 30, 2017 | 50.03 Bn |
| Mar 31, 2017 | 50.12 Bn |
| Dec 31, 2016 | 49.91 Bn |
| Sep 30, 2016 | 50.34 Bn |
| Jun 30, 2016 | 50.42 Bn |
| Mar 31, 2016 | 37.10 Bn |
| Dec 31, 2015 | 2.60 Bn |
| Sep 30, 2015 | 36.92 Bn |
| Jun 30, 2015 | 36.98 Bn |
| Mar 31, 2015 | 11.29 Bn |
| Dec 31, 2014 | 2.50 Bn |
| Sep 30, 2014 | 10.90 Bn |
| Jun 30, 2014 | 11.25 Bn |
| Mar 31, 2014 | 11.33 Bn |
| Dec 31, 2013 | 2.30 Bn |
| Sep 30, 2013 | 11.71 Bn |
| Jun 30, 2013 | 12.25 Bn |
| Mar 31, 2013 | 12.25 Bn |
| Dec 31, 2012 | 2.20 Bn |